Lpl Financial LLC Ardelyx, Inc. Transaction History

Lpl Financial LLC

$218 Billion
Q3 2024

A detailed history of Lpl Financial LLC transactions in Ardelyx, Inc. stock. As of the latest transaction made, Lpl Financial LLC holds 197,366 shares of ARDX stock, worth $1.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

197,366

Previous 193,054 2.23%

Holding current value

$1.1 Million

Previous $1.43 Million 4.97%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$5.28 - $7.57 $22,767 - $32,641	4,312 Added 2.23%	197,366 $1.36 Million
Q2 2024 Aug 07, 2024	BUY	$5.89 - $9.31 $376,477 - $595,076	63,918 Added 49.5%	193,054 $1.43 Million
Q1 2024 May 10, 2024	BUY	$6.05 - $9.74 $152,460 - $245,448	25,200 Added 24.25%	129,136 $942,000
Q4 2023 Feb 14, 2024	BUY	$3.29 - $6.64 $58,196 - $117,454	17,689 Added 20.51%	103,936 $644,000
Q3 2023 Nov 13, 2023	BUY	$3.3 - $4.83 $21,176 - $30,994	6,417 Added 8.04%	86,247 $351,000
Q2 2023 Jul 31, 2023	BUY	$3.23 - $4.95 $19,799 - $30,343	6,130 Added 8.32%	79,830 $270,000
Q1 2023 May 10, 2023	BUY	$2.68 - $4.79 $38,056 - $68,018	14,200 Added 23.87%	73,700 $353,000
Q4 2022 Feb 07, 2023	SELL	$1.22 - $2.85 $3,660 - $8,550	-3,000 Reduced 4.8%	59,500 $169,000
Q3 2022 Nov 14, 2022	BUY	$0.59 - $1.44 $8,260 - $20,160	14,000 Added 28.87%	62,500 $74,000
Q2 2022 Aug 12, 2022	BUY	$0.51 - $1.17 $51 - $117	100 Added 0.21%	48,500 $29,000
Q1 2022 May 16, 2022	BUY	$0.65 - $1.18 $15,600 - $28,320	24,000 Added 98.36%	48,400 $52,000
Q4 2021 Feb 14, 2022	BUY	$0.86 - $1.7 $7,912 - $15,640	9,200 Added 60.53%	24,400 $27,000
Q3 2021 Nov 15, 2021	BUY	$1.27 - $8.17 $19,304 - $124,184	15,200 New	15,200 $20,000

Others Institutions Holding ARDX

# of Institutions

218

Shares Held

142M

Call Options Held

1.08M

Put Options Held

View Full List

About ARDELYX, INC.

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $863M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

More about ARDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lpl Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lpl Financial LLC with notifications on news.

Account

Lpl Financial LLC Ardelyx, Inc. Transaction History